Mortality due to COVID-19 during the vaccination plan against the SARS-CoV-2 virus in Cali, Colombia

https://doi.org/10.25100/cm.v52i4.5047
COVID-19 COVID-19 Vaccines Pandemics SARS-CoV-2 Public Health Proportional Hazards Models Vaccination Coverage Health Services Accessibility

Article Sidebar

PDF PDF (Español) HTML HTML (Español)

Published: May 4, 2023
Updated: 2023-05-04
Versions:
2023-05-04 (2)
Issue: Vol. 52 No. 4 (2021)
Section Letters to editor

Publcation metrics

1112 | 744 | 634 | 137 | 114




 


Main Article Content

Authors
  •   Carlos Reina +
  •   Miyerlandi Torres +
  •   Edgar Muñoz +
  •   Elvia Karina Grillo Ardila +
  •   Rodrigo Guerrero +
  •   Luis Eduardo Bravo +
Abstract

The behavior of the COVID-19 pandemic during the three peaks registered in Cali has been heterogeneous, and the severity of infections and deaths has varied over time.  Cali, with 2.2 million inhabitants, is the third most populated city in Colombia; as of November 21, 2021, it has recorded 285 thousand confirmed cases and 7,474 deaths due to the infection. The vaccination plan against SARS-CoV-2, which was started in February, has immunized 1.54 million people in Cali.


As in the rest of the country, the development of the vaccination plan in Cali coincided with the third peak of the pandemic, the most lethal and prolonged; as well as with multiple social mobilizations of hundreds of protesters who crowded the streets, between May and June 2021, protesting against an unpopular tax reform enacted by the national government. In Cali, the vaccination plan was also affected by lack of access to health services and vaccination points due to blockages registered in different zones of the city. At the end of the third peak, the country faced difficulties in continuing with the vaccination plan due to barriers to accessing vaccines in the international market.

Author Biographies

Carlos Reina, Secretaria de Salud Pública del Municipio de Santiago de Cali, Colombia

orcid_id14.png https://orcid.org/0000-0002-6367-9239

Miyerlandi Torres, Secretaria de Salud Pública del Municipio de Santiago de Cali

orcid_id14.png https://orcid.org/0000-0002-3601-1858

Edgar Muñoz, University of Texas , Health Science Center San Antonio, Texas, USA

orcid_id14.png https://orcid.org/0000-0002-1555-8408

Elvia Karina Grillo Ardila, Universidad del Valle, Facultad de Salud, Doctorado en Salud, Cali, Colombia

orcid_id14.png http://orcid.org/0000-0001-9504-5153

Rodrigo Guerrero, Universidad del Valle, Instituto de Investigación y Desarrollo en Prevención de la Violencia y Promoción de la Convivencia Social, CISALVA, Cali, Colombia

orcid_id14.png https://orcid.org/0000-0002-4683-7987

Luis Eduardo Bravo, Universidad del Valle, Universidad del Valle, Facultad de Salud, Escuela de Medicina, Cali , Colombia, 6 Hospital Universitario del Valle “Evaristo García”, Cali, Colombia

orcid_id14.png http://orcid.org/0000-0002-9708-0312

How to Cite
Reina, C., Torres, M., Muñoz, E., Grillo Ardila, E. K., Guerrero, R., & Bravo, L. E. (2023). Mortality due to COVID-19 during the vaccination plan against the SARS-CoV-2 virus in Cali, Colombia. Colombia Medica, 52(4), e7005047. https://doi.org/10.25100/cm.v52i4.5047 (Original work published February 14, 2022)
References

Departamento Administrativo Nacional de Estadística (DANE). Proyecciones de población 2018-2023. DANE; 2020. Cited: 2021 Nov 21. Available from: https://www.dane.gov.co/index.php/estadisticas-por-tema/demografia-y-poblacion/proyecciones-de-poblacion.

Secretaria de Salud Pública. COVID19_21noviembre. Boletín Epidemiológico No.622. Cali: Alcaldia de Santiago de Cali; 2021. Available from: https://www.cali.gov.co/salud/publicaciones/152840/boletines-epidemiologicos/.

Secretaria de Salud Pública. COVID19_23noviembre. Boletín Vacunación COVID No.265. Cali: Alcaldia de Santiago de Cali; 2021. Cited: 2021 Nov 21. Available from: https://www.cali.gov.co/salud/publicaciones/159073/boletines-vacunacion-covid/

Jara A, Undurraga EA, González C, Paredes F, Fontecilla T, Jara G, et al. Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile. N Engl J Med. 2021; 385: 875-884. https://doi.org/10.1056/NEJMoa2107715

Thompson MG, Burgess JL, Naleway AL, Tyner HL, Yoon SK, Meece J, et al. Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers - eight u.s. locations, December 2020-March . MMWR Morb Mortal Wkly Rep. 2021;70(13):495-500. https://doi.org/10.15585/mmwr.mm7013e3

Kai X, Xiao-Yan T, Miao L, Zhang-Wu L, Jiang-Nan C, Jiao-Jiao L, et al. Efficacy and safety of COVID-19 vaccines: A systematic review. Chinese J Contemp Pediatr. 2021; 23(3):221-8. https://10.7499/j.issn.1008-8830.2101133

Higdon MM, Wahl B, Jones CB, Rosen JG, Truelove SA, Baidya A, et al. A systematic review of COVID-19 vaccine efficacy and effectiveness against SARS-CoV-2 infection and disease. medRxiv. 2021. https://doi.org/10.1101/2021.09.17.21263549

Goldman E. How the unvaccinated threaten the vaccinated for COVID-19: A Darwinian perspective. Proc Natl Acad Sci United States Am. 2021;118(39): e2114279118. https://doi.org/10.1073/pnas.2114279118

Usage statistics

Downloads

Download data is not yet available.
Most read articles by the same author(s)
<< < 1 2 3 4 5 > >> 
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

The copy rights of the articles published in Colombia Médica belong to the Universidad del Valle. The contents of the articles that appear in the Journal are exclusively the responsibility of the authors and do not necessarily reflect the opinions of the Editorial Committee of the Journal. It is allowed to reproduce the material published in Colombia Médica without prior authorization for non-commercial use